Clinical Spectrum and Complications of the Nephrotic Syndrome

Journal of Investigative Medicine

Volumn 45, Issue 4, 1997, Pages 143-153

  Abrass, Christine K ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDEMA; HUMAN; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; PROTEINURIA; REVIEW;

EDEMA; HUMANS; NEPHROTIC SYNDROME; PROTEINURIA;

EID: 0031112112     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (101)

1. Daniels BS. The role of the glomerular epithelial cell in the maintenance of the glomerular filtration barrier. Am J Nephrol 1993;13:318-23.
2. Myers BD, Guasch A. Selectivity of the glomerular filtration barrier in healthy and nephrotic humans. Am J Nephrol 1993;13:311-7.
3. Kanwar YS. Biophysiology of glomerular filtration and proteinuria. Lab Invest 1984;51:7-21.
4. Ota K, Shikata K, Makino H. The ultrastructural disruption of the glomerular basement membrane in diabetic nephropathy revealed by "tissue negative staining method." J Diabetes Complications 1995;9:285-7.
5. Caulfield JP, Farquhar MG. Identification and characterization of podocalyxin - the major sialoprotein of the renal glomerular epithelial cell. J Cell Biol 1984;98:1591-6.
6. Rodewald R, Karnovsky MJ. Porous substructure of the glomerular slit diaphragm in the rat and mouse. J Cell Biol 1974;60:423-33.
7. Cybulsky AV, Carbonetto S, Huang Q, et al. Adhesion of rat glomerular epithelial cells to extracellular matrices: role of 1-integrins. Kidney Int 1992;42:1099-106.
8. Kaysen GA. Plasma composition in the nephrotic syndrome. Am J Nephrol 1993;13:347-59.
9. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The hyperlipidemia of the nephrotic syndrome. N Engl J Med 1985;312:1544-8.
10. Kaysen GA. Nonrenal complications of the nephrotic syndrome. Annu Rev Med 1994;45:201-10.
11. Bernard DB. Extrarenal complications of the nephrotic syndrome. Kidney Int 1988;33:1184-202.
12. Ogi M, Yokoyama H, Tomosugi N, Hisada S, Ohta M, Takaneda T, Wada T, Naito K, Ikeda S, Goshima K, Takasawa K, Kobayashi K. Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. Am J Kidney Dis 1994;24:427-36.
13. Kees-Folts D, Diamond JR. Relationship between hyperlipidemia, lipid mediators, and progressive glomerulosclerosis in the nephrotic syndrome. Am J Nephrol 1993;13:365-75.
14. Fahal IH, McClelland P, Hay CR, Bell GM. Arterial thrombosis in the nephrotic syndrome. Postgrad Med J 1994;70:905-9.
15. Gugler R, Shoeman DW, Huffman DH, Cohlmia JB, Azarnoff DL. Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest 1975;55:1182-9.
16. Vrhovac B, Sarapa N, Bakran I, Huic V, Macolic-Sarinic V, Francetic I, Wolf-Coporda A, Plavsic F. Pharmacokinetic changes in patients with oedema. Clin Pharmacokinet 1995;28:405-18.
17. Bernard DB, Alexander EA. Edema formation in the nephrotic syndrome: pathophysiologic mechanisms. Cardiovascular Medicine 1979;4:605-25.
18. Valentin JP, Qiu C, Muldowney WP, Ying W, Gardner DG, Humphreys MH. Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome. J Clin Invest 1992;90:1302-12.
19. Martin PY, Schrier RW. Renal sodium excretion and edematous disorders. Endocrinol Metab Clin North Am 1995;24:459-79.
20. Perico N, Remuzzi G. Renal handling of sodium in the nephrotic syndrome. Am J Nephrol 1993;13:413-21.
21. Jespersen B, Eiskjaer H, Mogensen CE, et al. Reduced natriuretic effects of atrial natriuretic peptide in nephrotic syndrome: a possible role of decreased cyclic guanosine monophosphate. Nephron 1995;71:44-53.
22. Rabelink TJ, Bijlsma JA, Koomans HA. Iso-oncotic volume expansion in the nephrotic syndrome. Clin Sci (Colch) 1993;84:627-32.
23. Ueda N, Ninomi Y, Nonoda T. Urine kallikrein excretion in relation to renal sodium handling in minimal change nephrotic syndrome. Clin Nephrol 1991;36:228-33.
24. Koomans HA, Geers AB, Dorhout Mees EJ, Kortlandt W. Lowered tissue-fluid oncotic pressure protects the blood volume in the nephrotic syndrome. Nephron 1986;42:317-22.
25. Bansal R, Pfeiffer SE. Regulated galactolipid synthesis and cell surface expression in Schwann cell line D6P2T. J Neurochem 1987;49:1902-11.
26. Gandelman K, Pfeiffer SE, Carson JH. Cyclic AMP regulation of PO glycoprotein and myelin basic protein gene expression in semidifferentiated peripheral neurinoma cell line D6P2T. Development 1989;106:389-98.
27. Joles JA, Rabelink TJ, Braam B, Koomans HA. Plasma volume regulation: defenses against edema formation (with special emphasis on hypoproteinemia). Am J Nephrol 1993;13:399-412.
28. Ichikawa I, Rennke HG, Hoyer JR, Badr F, Schor N, Troy JL. Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Invest 1983;71:91-103.
29. Makker SP. Mediators of immune glomerular injury. Am J Nephrol 1993;13:324-36.
30. Baker CH, Abel FL. Macro- and microcirculatory effects of IL-15. Shock 1995;4:307-10.
31. Kohan DE. Interleukin-1 regulation of collecting duct prostaglandin E2 and cyclic nucleotide accumulation. J Lab Clin Med 1994;123:668-75.
32. Kato J, Misko TP, Currie MG. Induction of nitric oxide synthase regulates atrial natriuretic peptide receptors in vascular smooth muscle cells. Eur J Pharmacol 1993;244:153-9.
33. Markewitz BA, Michael JR, Kohan DE. Cytokine-induced expression of a nitric oxide synthase in rat renal tubule cells. J Clin Invest 1993;91:2138-43.
34. Lieberthal W, Bernard DB. Clinical relevance of the natriuretic peptides in edematous states. Curr Opin Nephrol Hypertens 1993;2:653-61.
35. Smith JD, Hayslett JP. Reversible renal failure in the nephrotic syndrome. Am J Kidney Dis 1992;19:201-13.
36. Galaske RG, Baldamus CA, Stolte H. Plasma protein handling in the rat kidney: micropuncture experiments in the heterologous phase of anti-GBM-nephritis. Pflugers Arch 1978;375:269-77.
37. Park CH, Maack T. Albumin absorption and catabolism by isolated perfused proximal convoluted tubules of the rabbit. J Clin Invest 1984;73:767-78.
38. Rothschild MA, Oratz M, Schreiber SS. Albumin synthesis. N Engl J Med 1972;286:748-57.
39. Kaysen GA, Ganbertoglio J, Jimenez I, Jones H, Hutchison FN. Effects of dietary protein intake on albumin homeostasis in nephrotic patients. Kidney Int 1986;29:572-7.
40. Short CD, Durrington PN, Mallick NP, et al. Serum and urinary high-density lipoproteins in glomerular disease with proteinuria. Kidney Int 1986;29:1224-8.
41. Gitlin D, Janeway CA, Farr LE. Studies on the metabolism of plasma proteins in the nephrotic syndrome. I. Albumin, gamma-globulin, and iron-binding globulin. J Clin Invest 1956;35:44-56.
42. Schreiner GE. Prevention of renal disease and conservation of renal function. Am J Kidney Dis 1990;16:360-6.
43. Thomas ME, Schreiner GF. Contribution of proteinuria to progressive renal injury: consequences of tubular uptake of fatty acid bearing albumin. Am J Nephrol 1993;13:385-98.
44. Barness LA, Moll GH, Janeway CA. Nephrotic syndrome. I. Natural history of the disease. Pediatrics 1950;5:486-503.
45. Krensky AM, Ingelfinger JR, Grupe WE, Peritonitis in childhood nephrotic syndrome. American Journal of Diseases in Childhood 1982;136:732-6.
46. Speck WT, Dresdale SS, McMillan RW. Primary peritonitis and the nephrotic syndrome. Am J Surg 1974;127:267-9.
47. Wilfert CM, Katz SL. Etiology of bacterial sepsis in nephrotic syndrome 1963-1967. Pediatrics 1968;42:840-3.
48. Harris RC, Ismail N. Extrarenal complications of the nephrotic syndrome. Am J Kidney Dis 1994;23:477-97.
49. Heslan JM, Lautie JP, Intrator L, Blanc C, Lagrue G, Sobel AT. Impaired IgG synthesis in patients with the nephrotic syndrome. Clin Nephrol 1982;18:144-7.
50. Garin EH, Sausville PJ, Richard GA. Impaired primary antibody response in experimental nephrotic syndrome. Clin Exp Immunol 1983;52:595-8.
51. Spika JS, Halsey NA, Le CT, Fish AJ, Lum GM, Lauer BA, Schiffman G, Giebink GS. Decline of vaccine-induced antipneumococcal antibody in children with nephrotic syndrome. Am J Kidney Dis 1986;7:466-70.
52. LaManna A, Polito C, Foglia AC, DiToro A, Cafaro MR, Del Gado R. Reduced ressponse to HBV vaccination in boys with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 1992;6:251-3.
53. Spika JS, Halsey NA, Fish AJ, Lum GM, Lauer BA, Schiffman G, Giebink GS. Serum antibody response to pneumococcal vaccine in children with nephrotic syndrome. Pediatrics 1982;69:219-23.
54. Warshaw BL, Check IJ, Hymes LC, DiRusso SC. Decreased serum transferrin concentration in children with nephrotic syndrome: effect on lymphocyte proliferation and correlation with serum immunoglobulin levels. Clin Immunol Immunopathol 1984;33:210-9.
55. Dardenne M, Pleau J, Nabarra B, Lefrancier P, Derrien M, Chay J, Bach J. Contribution of zinc and other metals to the biologic activity of the serum thymic factor. Proc Natl Acad Sci USA 1982;79:5370-3.
56. LLach F, Papper S, Massry SG. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of the nephrotic syndrome. Kidney Int 1985;28:429-39.
57. Cameron JS. Coagulation and thromboembolic complications of the nephrotic syndrome. Adv Nephrol Necker Hosp 1984;13:75-114.
58. Fuh JL, Teng MM, Yang WC, Liu HC. Cerebral infarction in young men with nephrotic syndrome. Stroke 1992;23:295-7.
59. Ganeval D, Fischer AM, Barre J, Pertuiset N, Dautzenberg MD, Jungers P, Houin G. Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. Clin Nephrol 1986;25:75-80.
60. Rostoker G, Durand-Zaleski I, Petit-Phar M, Ben-Maadi A, Jazaerli N, Radier C, Rashmouni A, Mathieu D, Vasile N, Rosso J. Prevention of thrombotic complications of the nephrotic syndrome by the low molecular weight heparin enoxaparin. Nephron 1995;69:20-8.
61. D'Amico GD, Gentile MG. Treatment of hyperlipidemia in human renal disease. Miner Electrolyte Metab 1993;19:196-204.
62. Joven J, Villabona C, Vilella E, Masana L, Alberti R, Valles M. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990;323:579-84.
63. Muls E, Rosseneu M, Daneels R, Schurger M, Boelaert J. Lipoprotein distribution and composition in the human nephrotic syndrome. Atherosclerosis 1985;54:225-37.
64. Wanner C, Rader D, Bartens W, Kramer J, Brewer HB Schollmeyer P, Wieland H. Elevated plasma lipoprotein (a) in patients with nephrotic syndrome. Ann Intern Med 1993;119:263-9.
65. Baxter JH, Goodman HC, Allen JC. Effects of infusions of serum albumin on serum lipids and lipoproteins in nephrosis. J Clin Invest 1961;49:490-8.
66. Davies RW, Staprans I, Hutchinson GN, Kaysen GA. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 1990;86:600-5.
67. Furukawa S, Hirano T, Mamo J, Nagano S, Takahashi T. Catabolic defect of triglyceride is associated with abnormal very-low-density lipoproteins in experimental nephrosis. Metabolism 1990;39:101-7.
68. Vaziri ND, Liang KH. Downregulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 1996;50:887-93.
69. Rosenman RH, Freidman M. In vivo studies of the role of albumin in endogenous and heparin-activated lipemia clearing in nephrotic rats. J Clin Invest 1957;36:700-10.
70. Kashyap ML, Spivastava LS, Hynd BA, Brady D, Perisutti C, Glueck C, Gartside PO. Apo protein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis 1980;35:29-40.
71. Staprans I, Garon SJ, Hopper J, Felts JM. Characterization of glycosaminoglycans in urine from patients with nephrotic syndrome and control subjects and their effects on lipoprotein lipase. Biochim Biophys Acta 1981;678:414-22.
72. Chait A, Heinecke JW. Lipoprotein modification: cellular mechanisms. Curr Opin Lipidol 1994;5:363-70.
73. Stenvinkel P, Berglund L, Heimburger O, Pettersson E, Alvestrand A. Lipoprotein (a) in nephrotic syndrome. Kidney Int 1993;44:1116-23.
74. Ordonez JD, Hiatt R, Killebrew E, Fireman B. The risk of coronary artery disease among patients with the nephrotic syndrome. Kidney Int 1990;37:243A.
75. Wheeler DC, Chana RS. Interactions between lipoproteins, glomerular cells, and matrix. Miner Electrolyte Metab 1993;19:149-64.
76. Grone EF, Abboud HE, Hohne M, Walli AK, Grone HJ, Stuker D, Robenek H, Wieland E, Seidel D. Actions of lipoproteins in cultured human mesangial cells: modulation by mitogenic vasoconstrictors. Am J Physiol 1992;263:F686-96.
77. Wasserman J, Santiago A, Holthofer H, Epstein M, Schlondorff D. Interactions of low-density lipoprotein with rat mesangial cells. Kidney Int 1989;35:1168-74.
78. Neugarten J, Schlondorff D. Lipoprotein interactions with glomerular cells and matrix. Contemp Issues In Nephrol 1991;24:173-206.
79. Moorhead JF. Lipids and progressive kidney disease. Kidney Int 1991;39:S35-40.
80. Appel GB, Appel AS. Lipid-lowering agents in proteinuric diseases. Am J Nephrol 1990;10(1 Suppl):110-5.
81. D'Amico G, Gentile MG. Pharmacologic and dietary treatment of lipid abnormalities in nephrotic patients. Kidney Int 1991;393(1 Suppl):S65-9.
82. Golper TA, Illingworth R, Morris CD, Bennett WM. Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. Am J Kidney Dis 1989;13:312-20.
83. Kuster S, Mehls O, Seidel C, Ritz E. Blood pressure in minimal change and other types of nephrotic syndrome. Am J Nephrol 1990;10 (1 Suppl):76-80.
84. Rostin M, Barthe P, Houin G, Alvinerie M, Bouissou F. Pharmacokinetics of prednisolone in children with nephrotic syndrome. Pediatr Nephrol 1990;4:470-3.
85. Miller PF, Bowmer CJ, Wheeldon J, Brocklebank JT. Pharmacokinetics of prednisolone in children with nephrosis. Arch Dis Child 1990;65:196-200.
86. Elias AN, Carreon G, Vaziri ND, Pandian MR, Oveisi F. The pituitary-gonadal axis in experimental nephrotic syndrome in male rats. J Lab Clin Med 1992;120:949-54.
87. Afrasiabi MA, Vaziri ND, Gwinup G, Mays DM, Barton CH, Ness R, Valenta LJ. Thyroid function studies in the nephrotic syndrome. Ann Intern Med 1979;90:335-8.
88. Vaziri ND, Kaupke CJ, Barton CH, Gonzales E. Plasma concentration and urinary excretion of erythropoietin in adult nephrotic syndrome. Am J Med 1992;92:35-40.
89. Zhou XJ, Vaziri ND. Erythropoietin metabolism and pharmacokinetics in experimental nephrosis. Am J Physiol 1992;263:F812-5.
90. Goldstein DA, Haldimann B, Sherman D, Norman AW, Massry SG. Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab 1981;52:116-21.
91. Malluche HH, Goldstein DA, Massry SG. Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J Clin Invest 1979;63:494-500.
92. Barragry JM, Carter ND, Beer M, France MW, Auton JA, Boucher BJ, Cohen RD. Vitamin-D metabolism in nephrotic syndrome. Lancet 1977;2:629-32.
93. Khamiseh G, Vaziri ND, Oveisi F, Ahmadnia MR, Ahmadnia L. Vitamin D absorption, plasma concentration, and urinary excretion of 25-hydroxyvitamin D in nephrotic syndrome. Proc Soc Exp Biol Med 1991;196:210-3.
94. Koenig KG, Lindberg JS, Zerwekh JE, Padalino PK, Cushner HM, Copley JB. Free and total 1,25-hydroxyvitamin D levels in subjects with renal disease. Kidney Int 1992;41:161-5.
95. Mizokuchi M, Kubota M, Tomino Y, Koide H. Vitamin D metabolism in nephrotic rats. Contrib Nephrol 1991;90:139-43.
96. Glassock RJ. Therapy of idiopathic nephrotic syndrome in adults. A conservative or aggressive therapeutic approach? Am J Nephrol 1993;13:422-8.
97. Olivero JJ, Frommer JP, Gonzalez JM. Medical nephrectomy: the last resort for intractable complications of the nephrotic syndrome. Am J Kidney Dis 1993;21:260-3.
98. Niaudet P, Habib R. Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol 1994;5:1049-56.
99. Haws RM, Baum M. Efficacy of albumin and diuretic therapy in children with nephrotic syndrome. Pediatrics 1993;91:1142-6.
100. Carome MA, Moore J Jr. Nephrotic syndrome in adults. A diagnostic and management challenge. Postgrad Med 1992;92:209-18.
101. Ruggeri M, Milan M, La Greca G, Castaman, G, Rodeghiero. Adult patients with the nephrotic syndrome: really at risk for deep venous thromboembolism? Report of a series and review of the literature. Haematologica 1993;78:47-51.